FTH · XBRL financial data
Faeth Therapeutics financial statements, every fiscal year
The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (FTH's year ends in late December)
| In thousands of dollars | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|
| General and administrative | 15,820 | 19,805 | 18,765 | 13,036 | 11,328 |
| Total operating expenses | 37,482 | 50,188 | 37,064 | 32,614 | 22,288 |
| Operating income (loss) | (37,482) | (50,188) | (37,064) | (32,614) | (22,288) |
| Interest expense | 670 | 219 | 144 | 90 | 32 |
| Other income (expense) | (9) | 36 | (215) | (3) | (4) |
| Income tax expense (benefit) | — | — | — | 0 | 0 |
| Net income (loss) | (36,794) | (48,588) | (34,101) | (30,157) | (21,085) |
| Earnings per share, basic‡ USD per share | (26.60) | (31.60) | (24.40) | (24.00) | (16.72) |
| Earnings per share, diluted‡ USD per share | (26.60) | (31.60) | (24.40) | (24.00) | (16.72) |
| Weighted average shares, basic‡ thousands of shares | 1,386 | 1,535 | 1,398 | 1,256 | 1,261 |
| Weighted average shares, diluted‡ thousands of shares | 1,386 | 1,535 | 1,398 | 1,256 | 1,261 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (June 2025); filings made before it reported them unadjusted.
Balance sheet
CSVFiscal years (FTH's year ends in late December)
| In thousands of dollars | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 7,159 | 17,795 | 13,011 | 9,994 | 8,668 |
| Marketable securities | 140,462 | 89,321 | 52,746 | 31,341 | 12,516 |
| Total current assets | 148,542 | 108,589 | 67,250 | 41,929 | 21,507 |
| Property and equipment, net | 4,644 | 2,049 | 1,165 | 417 | 82 |
| Right-of-use asset | — | 5,355 | 4,330 | 2,804 | 1,294 |
| Total assets | 153,225 | 118,375 | 74,374 | 45,361 | 22,902 |
| Accounts payable | — | — | 573 | 244 | 689 |
| Accrued liabilities | — | — | 900 | 847 | 715 |
| Total current liabilities | 4,889 | 9,066 | 5,643 | 5,448 | 4,251 |
| Lease liability, non-current | — | 4,323 | 3,001 | 1,429 | 59 |
| Total liabilities | 6,712 | 14,968 | 9,479 | 6,975 | 4,310 |
| Accumulated deficit | (149,206) | (197,794) | (231,895) | (262,052) | (283,137) |
| Total stockholders' equity | 146,513 | 103,407 | 64,895 | 38,386 | 18,592 |
| Total liabilities and equity | 153,225 | 118,375 | 74,374 | 45,361 | 22,902 |
| Common shares outstanding (cover page)‡ thousands of shares | 1,534 | 1,549 | 1,254 | 1,260 | 1,340 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (June 2025); filings made before it reported them unadjusted.
Cash flows
CSVFiscal years (FTH's year ends in late December)
| In thousands of dollars | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|
| Net income (loss) | (36,794) | (48,588) | (34,101) | (30,157) | (21,085) |
| Stock-based compensation | 5,657 | 5,812 | 4,454 | 3,135 | 1,274 |
| Depreciation and amortization | 685 | 614 | 571 | 551 | 122 |
| Net cash from operating activities | (30,259) | (39,026) | (32,023) | (24,670) | (20,453) |
| Purchases of property and equipment | 2,026 | 321 | 180 | 146 | 16 |
| Net cash from investing activities | (143,118) | 49,949 | 38,412 | 22,440 | 19,772 |
| Share repurchases | — | — | 10,384 | — | — |
| Net cash from financing activities | 163,940 | (287) | (11,173) | (787) | (645) |
| Net change in cash | (9,437) | 10,636 | (4,784) | (3,017) | (1,326) |
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
- A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Faeth Therapeutics | 14,180 | not reported | (13,002)* | 25.8M | 13.3 quarters | 10-QSep 30, 2026 |
| Zeo ScientifiX | 2,265 | not reported | not reported | 7.8M | — | 10-KTJun 30, 2026 |
| Sunshine Biopharma | 13,748 | 9,264 | (918)* | 3.9M | 15.0 quarters | 10-QJun 30, 2026 |
| Neuphoria Therapeutics | 19,866 | year only | 1,214* | 5.4M | — | 10-KJun 30, 2026 |
| CV Sciences | 266 | 2,985 | 20* | 225.8M | — | 10-QJun 30, 2026 |
| Minerva Neurosciences | 20,216 | not reported | (8,150)* | 49.8M | 8.6 quarters | 10-QSep 30, 2026 |
| Bolt Biotherapeutics | 12,860 | 5 | (6,540)* | 1.9M | 2.7 quarters | 10-QJun 30, 2026 |
| Intensity Therapeutics | 8,494 | not reported | (2,500)* | 3.3M | 3.8 quarters | 10-QSep 30, 2026 |
| Genprex | 15,154 | not reported | (5,139)* | 819,709 | 2.9 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.
Data on this page was fetched . The filing on SEC.gov is the record.